WP1130

inquiry

Cat No.

CEI-0264

Description

WP1130 can inhibit Bcr/Abl with IC50 of 1.8 uM.

CAS_No

856243-80-6

Molecular Weight

384.27

Purity

>99%

Storage

2 years at -20 centigrade

Targets

Bcr-Abl

Molecular Formula

C19H18BrN3O

Chemical Name

(S,E)-3-(6-bromopyridin-2-yl)-2-cyano-N-(1-phenylbutyl)acrylamide

Solubility

DSMO 77 mg/mL Water

In vitro

WP1130, is a second-generation tyrphostin derivative (degrasyn) discovered during screens for AG490-like molecules that suppress IL-6 and IL-3 activation of Stat molecules. WP1130 can reduce cytokine-stimulated Stat activation through the rapid down-regulation of upstream Jak kinases In CML cells, WP1130 induced down-regulation of Bcr/Abl protein without affecting bcr-abl mRNA levels. WP1130 speci?cally and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression in chronic myelogenous leukemia (CML) cells. WP1130 promotes Mcl-1 degradation and increases tumor cell sensitivity to chemotherapies. The combination of WP1130 and ABT-737, a well-documented Bcl-xL inhibitor, demonstrated a chemotherapeutic synergy and promoted apoptosis in different tumor cells.

In vivo

WP1130 suppresses the growth of K562 heterotransplanted tumors as well as both wild-type Bcr/Abl and T315I mutant Bcr/Abl-expressing BaF/3 cells transplanted into nude mice.

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry